As of May, 18 Biofrontera AG (BFRA) EPS Estimated At $-0.08

May 17, 2018 - By Amber Marburger

On May, 18 is expected Biofrontera AG (NASDAQ:BFRA)’s earnings report, as reported by RTT. After $-0.09 EPS was reported last quarter, analysts now see EPS growth of -11.11 % for Biofrontera AG. BFRA reached $13.67 during the last trading session after $0.06 change.Biofrontera AG is after having 0.00% since May 17, 2017. BFRA has 7,736 volume or 17.21% up from normal. BFRA underperformed by 11.55% the S&P 500.

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin.The firm is worth $298.10 million. The Company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin.Last it reported negative earnings. The firm is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis.

Another two news for Biofrontera AG (NASDAQ:BFRA) were briefly brought out by: Globenewswire.com on April 30, 2018 with title “Biofrontera Reports Full Year 2017 Financial Results”. The other Investingnews.com‘s article was titled “Pharmaceutical Update: Q1 in Review” and brought out on April 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: